AIM ImmunoTech Inc. (AIM) News
Filter AIM News Items
AIM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AIM News Highlights
- AIM's 30 day story count now stands at 3.
- Over the past 6 days, the trend for AIM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- MA are the most mentioned tickers in articles about AIM.
Latest AIM News From Around the Web
Below are the latest news stories about AIM IMMUNOTECH INC that investors may wish to consider to help them evaluate AIM as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday! |
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter – Phase 2 advanced recurrent ovarian cancer interim results expected Q3 2023 – Company to host conference call and webcast tomorrow at 8:30 AM ET OCALA, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or t |
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and WebcastOCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — announced today that management will host a conference call and webcast to discuss the Company’s Q1 2023 operational and financial results on Tuesday, May 16, 2023 at |
AIMIA ANNOUNCES CLOSING OF BOZZETTO TRANSACTIONAimia Inc. (TSX: AIM), a holding company focused on long-term global investments, is pleased to confirm that it has closed the previously announced acquisition of Giovanni Bozzetto S.p.A. (referred to as "Bozzetto Group", "Bozzetto", the "Company"). Bozzetto is one of the world's largest ESG-focused providers of specialty sustainable chemicals, serving over 1,500 clients with a portfolio of over 2,000 products. All amounts denominated in Euros below have been translated at the closing date of Ma |
AIMIA'S LARGEST SHAREHOLDER THANKS FELLOW SHAREHOLDERS FOR SUPPORTING CHANGE; MITHAQ EXPLORING ALL OPTIONS TO ENSURE VALIDITY OF RESULTSMithaq Capital SPC ("Mithaq"), the largest shareholder of Aimia Inc. (TSX: AIM) ("Aimia") holding 19.9% of Aimia's common shares, thanked the many fellow shareholders who cast their votes for change at the annual meeting of shareholders (the "Meeting") on April 18, 2023. Mithaq also announced that it is exploring all legal options to ensure the validity of the results and that Aimia has complied with corporate and securities laws in determining the outcome of the Meeting. |
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced the appointment of W. Neal Burnette, Ph.D., as Chairman of its Scientific Advis |
AIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINEMithaq Capital SPC ("Mithaq"), the largest shareholder of Aimia Inc. (TSX: AIM) ("Aimia") holding 19.9% of Aimia's common shares, reminds shareholders that time is quickly running out to vote their proxies "AGAINST" the entrenched board of directors (the "Board"). In order to be counted at the annual meeting of shareholders (the "Meeting"), proxies must be received by 10:30 a.m. (Eastern Daylight Time) on April 14, 2023. The Meeting is scheduled for April 18, 2023. |
AIMIA'S LARGEST SHAREHOLDER ENCOURAGES FELLOW SHAREHOLDERS TO VOTE AGAINST BOARDMithaq Capital SPC ("Mithaq"), the largest shareholder of Aimia Inc. (TSX: AIM) ("Aimia") holding 19.9% of Aimia's common shares, today outlined further reasons why it intends to vote against Aimia's underperforming and entrenched board of directors (the "Board") at the upcoming annual meeting of shareholders to be held on April 18, 2023 (the "Meeting"). |
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID ConditionsPreliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditionsOCALA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced central Institutional Review Board (“IRB”) approval for the protocol of its Phase 2 study |
AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones – Company to host inaugural conference call and webcast today at 8:30 AM ET OCALA, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, |